Un-audited results for quarter ended 31-12-2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hindustan Bio Sciences swung to a net profit of Rs. 8.20 lakhs in Q3 FY26 (Oct–Dec 2025), compared with a loss of Rs. 5.85 lakhs in the same quarter last year. Total revenue for the quarter stood at Rs. 40.03 lakhs versus just Rs. 0.88 lakhs a year ago, though it fell sharply from Rs. 74.39 lakhs in the preceding quarter (Q2 FY26). For the nine months ended Dec 2025, the company posted a profit of Rs. 3.74 lakhs against a loss of Rs. 0.98 lakhs in the corresponding period of FY25. Total operating revenue for 9M FY26 was Rs. 42.20 lakhs. The company's reserves remain in the red at negative Rs. 114.52 lakhs. The auditor VASG & Associates issued a clean (unmodified) limited review report.
The year-on-year return to profitability is a positive signal, but the steep sequential revenue drop and persistently negative reserves indicate the business is still small, volatile and financially weak — so shareholders should expect bumpy earnings and limited cushion.